CHMP Recommends Conditional Marketing Authorization for Pfizer's Leukemia Drug
January 23, 2013
CHMP Recommends Conditional Marketing Authorization for Pfizer's Leukemia Drug
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- European Regulators Grant Conditional Approval for Pfizer's Xalkori; Abbott Begins Marketing ALK CDx
October 24, 2012 / Pharmacogenomics Reporter - FDA Approves Pfizer's Chronic Philadelphia Chromosome-Positive CML Drug Bosulif
September 5, 2012 / Pharmacogenomics Reporter - Roche Gets Positive CHMP Review for Tarceva as First-line Treatment in EGFR-mutated NSCLC
July 27, 2011 / Pharmacogenomics Reporter - Pfizer, Abbott Plan Parallel Filing for FDA Approval of NSCLC Drug Crizotinib, FISH Test
January 19, 2011 / Pharmacogenomics Reporter - PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter